HYAL1 and cancer: In the top 10 pathways that are predicted to be altered due to HYAL1 overexpression, the “Osteoarthritis Pathway” was significantly inactivated (Z‐score<−6), and “HMGB1 (high-mobility group box 1) signaling” and “Endocannabinoid Cancer Inhibitory Pathway” were significantly activated (Z-score of approximately +5).